Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.
Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S160-3. Epub 2010 Oct 28.
Systemic sclerosis (scleroderma, SSc) and mixed connective tissue disease (MCTD) are chronic autoimmune diseases characterised by a broad spectrum of clinical manifestations including different forms of musculoskeletal involvement, skin and vascular changes, as well as internal organ complications. Clinical course and outcomes might vary from mild forms with good clinical prognosis to severe rapidly progressive life-threatening diseases. At present, immunosuppressive therapies are considered a cornerstone in the treatment of MCTD, and are frequently used in clinical practice in SSc despite limited evidence from clinical trials. The aim of the present review is to discuss available data concerning efficacy of methotrexate therapy in SSc and MCTD.
系统性硬化症（硬皮病，SSc）和混合性结缔组织病（MCTD）是慢性自身免疫性疾病，其特征是临床表现广泛，包括不同形式的肌肉骨骼受累、皮肤和血管变化以及内脏器官并发症。临床过程和结局可能从预后良好的轻度形式到严重的快速进展性危及生命的疾病不等。目前，免疫抑制疗法被认为是 MCTD 治疗的基石，并且尽管临床试验证据有限，但在 SSc 中也经常在临床实践中使用。本综述的目的是讨论关于甲氨蝶呤治疗 SSc 和 MCTD 的疗效的现有数据。
